Cover Image

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Jannis Kountouras, Stergios A. Polyzos, Evangelos Kazakos, Ioannis S. Papanikolaou, Christos Liatsos, Elisabeth Vardaka, Dimitrios Tzilves, Efthimia Vlachaki
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH
by: Jannis Kountouras, et al.
Published: (2024)

Letter: H. pylori Infection May Constitute a Risk Factor for Reflux Disease and Colonic Neoplasia
by: Jannis Kountouras, et al.
Published: (2025)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
by: Jannis Kountouras, et al.
Published: (2024)

Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
by: Stergios A. Polyzos, et al.
Published: (2024)

A Potential Impact of Helicobacter pylori Infection on Gastroesophageal Reflux Disease
by: Jannis Kountouras, et al.
Published: (2026)

Helicobacter pylori Infection and Cholelithiasis
by: Evangelos Kazakos, et al.
Published: (2024)

Helicobacter pylori and Porphyromonas gingivalis Infections as Potential Risk Predictors for Gastric Cancer and Two Types of Esophageal Cancer
by: Jannis Kountouras, et al.
Published: (2026)

Helicobacter pylori and Metabolic Syndrome‐Related Mast Cells May Be Potential Risk Factors for the Increased Prevalence of Barrett's Esophagus
by: Jannis Kountouras, et al.
Published: (2025)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition?
by: Fernanda Cristofori, et al.
Published: (2025)

Helicobacter pylori Eradication Regimens With Adjuvant Probiotics Efficacy in the Treatment of Hepatic Encephalopathy
by: Jannis Kountouras, et al.
Published: (2025)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition? Authors' Reply
by: Irene Spinelli, et al.
Published: (2025)

Letter: Meta‐Analysis Critique: Refining the Association Between Helicobacter pylori and Eosinophilic Oesophagitis
by: Haleema Rahman
Published: (2025)

Letter: Disappearing Microbe, Emerging Disease? Nuancing the Protective Effects of Helicobacter pylori Against Eosinophilic Oesophagitis
by: Enzo Emanuele, et al.
Published: (2025)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
by: Francisco Idalsoaga, et al.
Published: (2024)

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH—Authors’ reply
by: S. K. Bansal, et al.
Published: (2024)

Letter: Disappearing Microbe, Emerging Disease? Nuancing the Protective Effects of Helicobacter pylori Against Eosinophilic Oesophagitis. Authors' Reply
by: Irene Spinelli, et al.
Published: (2025)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
by: Stuart McPherson, et al.
Published: (2024)

Relationship between Helicobacter pylori and metabolic syndrome‐related parameters and risk of MASLD
by: Jannis Kountouras, et al.
Published: (2024)

Letter: Clarifying the Synergistic Mechanisms of Mediterranean Diet and Time‐Restricted Feeding in MASLD Management—Authors' Reply
by: Sofia Tsitsou, et al.
Published: (2025)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
by: Jian Wang, et al.
Published: (2024)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
by: Jiamei Wang, et al.
Published: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
by: Yaomin Wang, et al.
Published: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
by: Zhuo Li, et al.
Published: (2024)

Helicobacter pylori‐Associated Surrogate Markers of Intestinal Permeability, Bacterial Translocation and Gut Barrier Damage in Liver Cirrhosis
by: Jannis Kountouras, et al.
Published: (2025)

Vitamin E in Metabolic Dysfunction‐Associated Steatotic Liver Disease
by: Stergios A. Polyzos, et al.
Published: (2024)

Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection—Questions Focused on Clinical Practice
by: Javier P. Gisbert, et al.
Published: (2026)

Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases
by: Ivan Arcari, et al.
Published: (2024)

An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury
by: Mar Riveiro‐Barciela, et al.
Published: (2024)

Helicobacter pylori and metabolic syndrome‐related adipokines in nonalcoholic fatty liver disease pathophysiology
by: J Kountouras, et al.
Published: (2024)

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
by: Nina Dominik, et al.
Published: (2024)

Letter: MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls
by: Junbin Yan, et al.
Published: (2024)

Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma
by: Enrico N. De Toni, et al.
Published: (2024)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
by: Wenjun Meng, et al.
Published: (2024)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
by: Rui Zhang, et al.
Published: (2024)

Letter: Enhancing patient support through social work—Addressing economic challenges and medication non‐adherence in liver disease management
by: Min Wu, et al.
Published: (2024)

Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2–F3 fibrosis
by: Yusuf Yilmaz
Published: (2024)

Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2‐F3 fibrosis. Authors' reply
by: Stuart McPherson, et al.
Published: (2024)

Duke Activity Status Index and Liver Frailty Index predict mortality in ambulatory patients with advanced chronic liver disease: A prospective, observational study
by: Felicity R. Williams, et al.
Published: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
by: Sung Won Chung, et al.
Published: (2024)

Editorial: H. pylori Antimicrobial Susceptibility Testing—An Expanding Toolbox
by: Suvithan Rajadurai, et al.
Published: (2024)